CAMO Software User Meeting 2015 to take place in Prague
CAMO Software will be arranging their 2015 User Meeting in Prague, Czech Republic on 16th – 17th April...
List view / Grid view
News
Actavis receives FDA approval of SAPHRIS® for pediatric patients (age 10-17) for acute treatment of manic or mixed episodes of bipolar I disorder
13 March 2015 | By Actavis
Actavis plc announced that the U.S. Food and Drug Administration has approved its supplemental new drug application (sNDA) for SAPHRIS® (asenapine) as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients...
Novartis to present new late-breaking Cosentyx data at AAD 2015 showing significant patient benefit in achieving clear skin
13 March 2015 | By Novartis
Novartis announced that new results for Cosentyx(TM) (secukinumab) in moderate-to-severe plaque psoriasis, including detailed findings from the head-to-head CLEAR study and long-term data from the Phase III program, will be presented as late breaking research at the 73rd Annual Meeting of American Academy of Dermatology...
Statement on child health: responding to annual report by CYPHOF
12 March 2015 | By The National Children’s Bureau
Anna Feuchtwang, Chief Executive of the National Children’s Bureau, said: “The National Children’s Bureau, welcomes the Children and Young People’s Health Outcomes Forum’s (CYPHOF) annual report, which shows that despite improvements, progress on child health outcomes has not been fast enough in children and young people’s health care services..."
NHS Confederation response to NHS England’s plans for redesigning care
12 March 2015 | By NHS Confederation
Responding to NHS England’s announcement on transforming patient care, Rob Webster, chief executive of the NHS Confederation, said: “Today’s naming of 29 vanguard sites, many of which are our members, is to be welcomed..."
UK military healthcare worker in Sierra Leone tests positive for Ebola
12 March 2015 | By Public Health England Press Office
"We can confirm that a UK military healthcare worker in Sierra Leone has tested positive for Ebola. Medical experts are currently assessing the situation to ensure that appropriate care is delivered..."
European backing for two new Scottish hospitals confirmed
11 March 2015 | By The European Investment Bank
The European Investment Bank has agreed to provide GBP 109 million for the construction of a new District and General Hospital in Dumfries that will ensure modern health-care for people living in the south-west of Scotland...
Tresiba® (insulin degludec) approved in the EU for treatment of children and adolescents with diabetes
11 March 2015 | By Novo Nordisk
Latest data announced at Diabetes UK reinforces the long-term efficacy and safety of insulin degludec in children and adolescents with type 1 diabetes...
Declining Ebola cases pose serious challenge to clinical studies, says GlobalData analyst
11 March 2015 | By GlobalData
The steady decline in new Ebola cases presents a formidable challenge to current and future clinical trials of investigational treatments for the disease, as it will be more difficult to recruit study participants and demonstrate efficacy, says an analyst with research and consulting firm GlobalData...
NICE says ‘yes’ to new blood cancer drug
11 March 2015 | By Roche
New option for patients as NICE accepts Gazyvaro® (obinutuzumab) for treatment of most common adult leukaemia...
Big Pharma drives innovation in pain therapy development, despite declining patent applications, says GBI Research
10 March 2015 | By GBI Research
Patent applications for novel pain therapeutics declined steadily in number from 4,970 in 2008 to 3,492 in 2012, an average annual decrease of 8%, as limited understanding of pain pathophysiology continues to hinder drug development in this arena, says business intelligence provider GBI Research...
New data shows blood glucose, CV risk factors and quality of life outcomes improvement with Saxenda®
9 March 2015 | By Novo Nordisk
New data from the phase 3a SCALE™ Obesity and Prediabetes trial were presented at The Endocrine Society’s 97th Annual Meeting (ENDO), showing that adults with obesity or who are overweight with comorbidities who had lost ≥5% of their body weight at 56 weeks (ie weight loss responders), demonstrated greater improvements…
Gilead receives approval from the Scottish Medicines Consortium for use of zydelig® (idelalisib) for the treatment of chronic lymphocytic leukaemia
9 March 2015 | By Gilead Sciences
New oral treatment for Chronic Lymphocytic Leukaemia now approved for use within NHS Scotland...
AbbVie acquires Pharmacyclics to help secure future cash flows as Humira biosimilars loom
6 March 2015 | By GlobalData
“AbbVie’s acquisition of Pharmacyclics (PCYC), valued at $21 billion, will help the company alleviate its dependency on Humira, which accounted for 62% of its total revenues in 2014, up from 57% in 2013..."
AOP Orphan Pharmaceuticals announces progress of pivotal phase III trial PROUD-PV
6 March 2015 | By AOP Orphan
AOP Orphan Pharmaceuticals AG reported the completion of recruitment for its phase III trial PROUD-PV to support global licensure of Ropeginterferon alfa 2b (AOP2014/P1101), a novel, long-acting, mono-pegylated Interferon for the treatment of Polycythemia Vera...
